92 related articles for article (PubMed ID: 439107)
1. Cytotoxicity in progressive systemic sclerosis: no evidence for increased cytotoxicity against fibroblasts of different origin.
Cooper SM; Friou GJ
J Rheumatol; 1979; 6(1):25-9. PubMed ID: 439107
[TBL] [Abstract][Full Text] [Related]
2. Antibody-dependent cellular cytotoxicity of human vascular endothelium in systemic sclerosis.
Penning CA; Cunningham J; French MA; Harrison G; Rowell NR; Hughes P
Clin Exp Immunol; 1984 Sep; 57(3):548-56. PubMed ID: 6467679
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous antigen-stimulating lymphokine production by lymphocytes of patients with progressive systemic sclerosis (scleroderma).
Kondo H; Rabin BS; Rodnan GP
J Clin Invest; 1976 Dec; 58(6):1388-94. PubMed ID: 791970
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis.
Chizzolini C; Raschi E; Rezzonico R; Testoni C; Mallone R; Gabrielli A; Facchini A; Del Papa N; Borghi MO; Dayer JM; Meroni PL
Arthritis Rheum; 2002 Jun; 46(6):1602-13. PubMed ID: 12115192
[TBL] [Abstract][Full Text] [Related]
5. Selective decrease in antibody-dependent cell-mediated cytotoxicity in systemic lupus erythematosus and progressive systemic sclerosis.
Cooper SM; Harding B; Mirick GR; Schneider J; Quismorio FP; Friou GJ
Clin Exp Immunol; 1978 Nov; 34(2):235-40. PubMed ID: 737908
[TBL] [Abstract][Full Text] [Related]
6. Serum-induced enhancement of peripheral blood mononuclear cell-mediated cytotoxicity towards human target cells in systemic sclerosis.
Penning CA; Wright JK; Ashby JC; Cunningham J; Rowell NR; Hughes P
J Clin Lab Immunol; 1983 Oct; 12(2):77-81. PubMed ID: 6644792
[TBL] [Abstract][Full Text] [Related]
7. Antibody-dependent and phytohaemagglutinin-induced lymphocyte cytotoxicity in systemic sclerosis.
Wright JK; Hughes P; Rowell NR; Sneddon IB
Clin Exp Immunol; 1979 Apr; 36(1):175-82. PubMed ID: 466860
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts.
Chizzolini C; Rezzonico R; Ribbens C; Burger D; Wollheim FA; Dayer JM
Arthritis Rheum; 1998 Nov; 41(11):2039-47. PubMed ID: 9811060
[TBL] [Abstract][Full Text] [Related]
9. Expression of hepatocyte growth factor and its receptor (c-met) in skin fibroblasts from patients with systemic sclerosis.
Kawaguchi Y; Harigai M; Hara M; Fukasawa C; Takagi K; Tanaka M; Tanaka E; Nishimagi E; Kamatani N
J Rheumatol; 2002 Sep; 29(9):1877-83. PubMed ID: 12233882
[TBL] [Abstract][Full Text] [Related]
10. Anti-fibroblast antibodies detected by cell-based ELISA in systemic sclerosis enhance the collagenolytic activity and matrix metalloproteinase-1 production in dermal fibroblasts.
Fineschi S; Cozzi F; Burger D; Dayer JM; Meroni PL; Chizzolini C
Rheumatology (Oxford); 2007 Dec; 46(12):1779-85. PubMed ID: 17982166
[TBL] [Abstract][Full Text] [Related]
11. The immunobiology of systemic sclerosis.
Gu YS; Kong J; Cheema GS; Keen CL; Wick G; Gershwin ME
Semin Arthritis Rheum; 2008 Oct; 38(2):132-60. PubMed ID: 18221988
[TBL] [Abstract][Full Text] [Related]
12. Levels of cytotoxic reactivity to cultured normal skin fibroblasts in sera from normal and sarcoma-bearing patients.
Catapano MS; Brown JM; Rosenberg SA
Cancer Res; 1980 Apr; 40(4):979-83. PubMed ID: 6928402
[TBL] [Abstract][Full Text] [Related]
13. Intracellular IL-1 receptor antagonist is elevated in human dermal fibroblasts that overexpress intracellular precursor IL-1 alpha.
Higgins GC; Wu Y; Postlethwaite AE
J Immunol; 1999 Oct; 163(7):3969-75. PubMed ID: 10490999
[TBL] [Abstract][Full Text] [Related]
14. Sera from patients with scleroderma inhibit fibroblast micromotions monitored electrically.
Huang CN; Lo CM; Hsu TC; Tsay GJ
J Rheumatol; 1999 Jun; 26(6):1312-7. PubMed ID: 10381049
[TBL] [Abstract][Full Text] [Related]
15. Autoantibody to gp50, a glycoprotein shared in common between fibroblasts and lymphocytes, in progressive systemic sclerosis.
Alderuccio F; Witherden D; Toh BH; Barnett A
Clin Exp Immunol; 1989 Oct; 78(1):26-30. PubMed ID: 2805420
[TBL] [Abstract][Full Text] [Related]
16. Evidence for cell-mediated immunity to collagen in progressive systemic sclerosis.
Stuart JM; Postlethwaite AE; Kang AH
J Lab Clin Med; 1976 Oct; 88(4):601-7. PubMed ID: 965811
[TBL] [Abstract][Full Text] [Related]
17. [Studies of the mechanism of disorders of the natural killer cell activity in patients with systemic scleroderma].
Rudnicka L; Majewski S; Błaszczyk M; Skiendzielewska A; Makieła B
Przegl Dermatol; 1990; 77(4):252-4. PubMed ID: 2267353
[TBL] [Abstract][Full Text] [Related]
18. Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha.
Chizzolini C; Parel Y; De Luca C; Tyndall A; Akesson A; Scheja A; Dayer JM
Arthritis Rheum; 2003 Sep; 48(9):2593-604. PubMed ID: 13130479
[TBL] [Abstract][Full Text] [Related]
19. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis.
Hénault J; Tremblay M; Clément I; Raymond Y; Senécal JL
Arthritis Rheum; 2004 Oct; 50(10):3265-74. PubMed ID: 15476238
[TBL] [Abstract][Full Text] [Related]
20. Predictors of the scleroderma phenotype in fibroblasts from systemic sclerosis patients.
Qi Q; Guo Q; Tan G; Mao Y; Tang H; Zhou C; Zeng F
J Eur Acad Dermatol Venereol; 2009 Feb; 23(2):160-8. PubMed ID: 19054252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
